Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ethambutol Hydrochloride

FDA-approved product (tablet, oral), marketed as Ethambutol Hydrochloride, Myambutol.

Registered studies
50+
Lab records
52
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ethambutol Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK02

Repurposing investigation

Ethambutol Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli10.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae9.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 46 of 52 lab records
Open Ethambutol Hydrochloride in ChEMBL Registered studies below
Show the 52 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ethambutol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Intravenous Treatment of Tuberculosis

    NCT04150367 · start 2017-03-03

    Registered record
    Registry ID
    NCT04150367
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Ethambutol; Rifampicin; Isoniazid; Ethambutol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-03-03
    Completion
    2018-07-14
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Ethambutol; Rifampicin +2 more
    PhaseNot recorded
    Registry statusTerminated

  • Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

    NCT02901288 · start 2016-08

    Registered record
    Registry ID
    NCT02901288
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    Isoniazid; Rifampicin; Pyrazinamide; Ethambutol; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2018-12
    Enrolment
    3,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionIsoniazid; Rifampicin; Pyrazinamide; Ethambutol +1 more
    PhasePhase 4
    Registry statusUnknown

  • The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT02409290 · start 2016-03

    Registered record
    Registry ID
    NCT02409290
    Conditions
    MDR-TB
    Interventions
    Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline); Moxifloxacin; Clofazimine; Ethambutol; Pyrazinamide; Isoniazid; Prothionamide; Kanamycin; Levofloxacin; Bedaquiline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03
    Completion
    2023-05-02
    Enrolment
    588

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDR-TB
    InterventionRegimen A locally-used WHO-approved MDR-TB regimen (2011 guideline); Moxifloxacin; Clofazimine; Ethambutol +6 more
    PhasePhase 3
    Registry statusCompleted

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted

  • Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

    NCT02024555 · start 2014-03

    Registered record
    Registry ID
    NCT02024555
    Conditions
    Sarcoidosis; Antimycobacterial Therapy
    Interventions
    Levofloxacin; Ethambutol; Azithromycin; Rifampin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2019-04-01
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoidosis; Antimycobacterial Therapy
    InterventionLevofloxacin; Ethambutol; Azithromycin; Rifampin +1 more
    PhasePhase 2
    Registry statusCompleted

  • Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

    NCT01601626 · start 2013-07-13

    Registered record
    Registry ID
    NCT01601626
    Conditions
    HIV Infection; Tuberculosis
    Interventions
    Standard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid; Pyridoxine; Pyrazinamide; Ethambutol; Rifabutin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07-13
    Completion
    2017-06-28
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Tuberculosis
    InterventionStandard-dose Lopinavir/Ritonavir; Double-dose Lopinavir/Ritonavir; Raltegravir; Isoniazid +5 more
    PhasePhase 2
    Registry statusTerminated

  • Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes

    NCT01782950 · start 2013-02

    Registered record
    Registry ID
    NCT01782950
    Conditions
    AIDS With Tuberculosis
    Interventions
    Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-02
    Completion
    2016-03
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS With Tuberculosis
    InterventionRifampicin, Isoniazid, Ethambutol, Pyrazinamide
    PhasePhase 4
    Registry statusUnknown

  • A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults

    NCT01399788 · start 2011-07

    Registered record
    Registry ID
    NCT01399788
    Conditions
    Healthy Volunteers
    Interventions
    Myrin P Forte; Single drug references
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMyrin P Forte; Single drug references
    PhasePhase 1
    Registry statusCompleted

  • Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

    NCT01169038 · start 2010-07

    Registered record
    Registry ID
    NCT01169038
    Conditions
    Pulmonary Sarcoidosis; Lung Function
    Interventions
    levaquin; ethambutol; rifampin and azithromycin.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2010-11
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Sarcoidosis; Lung Function
    Interventionlevaquin; ethambutol; rifampin and azithromycin.
    PhasePhase 1
    Registry statusCompleted

  • Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

    NCT00728507 · start 2009-11

    Registered record
    Registry ID
    NCT00728507
    Conditions
    Tuberculosis
    Interventions
    Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2013-04
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    PhasePhase 2
    Registry statusTerminated

  • Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

    NCT00495326 · start 2007-12

    Registered record
    Registry ID
    NCT00495326
    Conditions
    Tuberculosis; Aids; Hiv Infections
    Interventions
    Nevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2011-04
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Aids; Hiv Infections
    InterventionNevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Tuberculosis Treatment Shortening Trial

    NCT00130247 · start 2002-04-08

    Registered record
    Registry ID
    NCT00130247
    Conditions
    Tuberculosis
    Interventions
    Ethambutol; Isoniazid; Pyrazinamide; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04-08
    Completion
    2008-11-28
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionEthambutol; Isoniazid; Pyrazinamide; Rifampin
    PhasePhase 3
    Registry statusCompleted

  • Preventive Therapy for Tuberculosis in HIV Infected Persons

    NCT00351702 · start 2001-02

    Registered record
    Registry ID
    NCT00351702
    Conditions
    Human Immunodeficiency Virus; Tuberculosis
    Interventions
    Isoniazid with Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2011-06
    Enrolment
    683

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus; Tuberculosis
    InterventionIsoniazid with Ethambutol
    PhasePhase 3
    Registry statusCompleted